Last reviewed · How we verify
NCT06236165
Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With Hepatic and Post Hepatic Jaundice
Phase 2 trial testing N-acetylcysteine in Hepatic and Post Hepatic Jaundice in 44 participants. Completed in 22 January 2025.
22 January 2025
Quick facts
| Lead sponsor | Tanta University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 14 February 2024 |
| Primary completion | 22 January 2025 |
| Estimated completion | 22 January 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- N-acetylcysteine — full drug profile →
Conditions studied
- Hepatic and Post Hepatic Jaundice — all drugs for Hepatic and Post Hepatic Jaundice →
Sponsor
Tanta University
Who can join
Adults 18 to 70, any sex, with Hepatic and Post Hepatic Jaundice. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigating the efficacy, safety, and molecular mechanism of N-acetylcysteine supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06236165
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of N-acetylcysteine
Trials testing the same drug.
- NCT05074121 — NAC for Attenuation of COVID-19 Symptomatology · Phase 2 · unknown
- NCT05494398 — Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label · Phase 2, PHASE3 · enrolling by invitation
- NCT05706402 — N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of COPD · Phase 3 · unknown
- NCT00775476 — Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine · Phase 2 · recruiting
- NCT05604586 — Assessment of the Impact of N-acetylcysteine Supplementation on Physical Performance · NA · unknown
Other Tanta University trials
Trials by the same sponsor.
- NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
- NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
- NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
- NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
- NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06236165 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tanta University
- Last refreshed: 30 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06236165.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing